Quest Partners LLC Acquires Shares of 10,086 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Quest Partners LLC acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the third quarter, according to its most recent filing with the SEC. The firm acquired 10,086 shares of the company’s stock, valued at approximately $84,000.

A number of other hedge funds have also recently bought and sold shares of AMRX. Vanguard Group Inc. boosted its position in shares of Amneal Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock worth $83,193,000 after purchasing an additional 85,846 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Amneal Pharmaceuticals by 417.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 36,106 shares of the company’s stock worth $218,000 after purchasing an additional 29,133 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Amneal Pharmaceuticals by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company’s stock worth $493,000 after purchasing an additional 5,146 shares during the last quarter. Bayesian Capital Management LP bought a new position in shares of Amneal Pharmaceuticals in the 1st quarter worth $65,000. Finally, California State Teachers Retirement System boosted its position in shares of Amneal Pharmaceuticals by 5.4% in the 1st quarter. California State Teachers Retirement System now owns 122,504 shares of the company’s stock worth $742,000 after purchasing an additional 6,321 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares of the company’s stock, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AMRX. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Truist Financial raised their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Barclays raised their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research note on Friday, September 6th. Finally, Piper Sandler raised their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Down 1.0 %

Shares of Amneal Pharmaceuticals stock opened at $8.27 on Friday. The stock’s fifty day simple moving average is $8.52 and its 200 day simple moving average is $7.78. Amneal Pharmaceuticals, Inc. has a 12 month low of $4.17 and a 12 month high of $9.48. The company has a market capitalization of $2.56 billion, a PE ratio of -12.16 and a beta of 1.17.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.